 |
Achieving Targets in Type 2 Diabetes: Interactive Patient Cases CME Dwight M. Deter, PA-C, Chair; Davida F. Kruger, MSN, APRN-BC, BC-ADM Author Information and Disclosures Release Date: May 28, 2008; Valid for credit through May 28, 2009 | Physicians - maximum of 2.75 AMA PRA Category 1 Credit(s)™ for physicians
Physician Assitants - maximum of 2.75 hours of AAPA Category 1 CME credit
Nurse Practitioners - This program has been approved for 2.75 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0804177. | | This CME activity, "Achieving Targets in Type 2 Diabetes: Interactive Patient Cases," was designed as an interactive patient simulation for release on Medscape.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 DIME |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Identify cardiovascular and glycemic target guidelines for patients with type 2 diabetes.
- Assess various therapies and their impacts on the cardiovascular
health of patients with type 2 diabetes.
- Incorporate incretin mimetics into current treatment paradigms for type 2 diabetes.
Author Disclosures Dwight M. Deter, PA-C
Disclosure: Consultant: Abbott Laboratories, Depomed, Inc., Genentech, Inc.,
GlaxoSmithKline, King Pharmaceuticals, Inc., sanofi-aventis Group; Speakers' Bureau/Honorarium: Abbott Laboratories, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corp., Pfizer Inc, sanofi-aventis Group
Mr. Deter does not intend to discuss unlabeled/unapproved use of drugs or devices.
Davida F. Kruger, MSN, APRN-BC, BC-ADM
Disclosure:
Grant/Research Support: Amylin Pharmaceuticals, Inc., Eli Lilly and Company; Consultant/Advisory Board Memberships: Abbott Laboratories, AgaMatrix, Inc., Amylin Pharmaceuticals, Inc., Animas Corporation, Eli Lilly and Company, Home Diagnostics, Inc., Patton Medical Devices, LP, Novo Nordisk A/S; Speakers' Bureau/Honorarium: Abbott Laboratories, AgaMatrix, Inc., Amylin Pharmaceuticals, Inc., Animas Corporation, Eli Lilly and Company, Home Diagnostics, Inc., Novo Nordisk A/S,
sanofi-aventis Group, Takeda Pharmaceuticals America, Inc; Financial Interests/Stock Ownership: Amylin Pharmaceuticals, Inc., DexCom, Inc., Patton Medical Devices, LP
Ms. Kruger does not intend to discuss unlabeled/unapproved use of drugs or devices.
|
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Discovery Institute of Medical Education (DIME). DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
DIME designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™.  This program has been reviewed and is approved for a maximum of 2.75 hours of AAPA
Category I CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of May 28, 2008. Participants may submit the self-assessment at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Successful completion of the self-assessment is required to earn
Category I CME credit. Successful completion is defined as a cumulative score of at least 70% correct. This program has been approved for 2.75 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0804177.
Contact This Provider
|
|
